Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5660329 | 0.82 | L3MBTL1 (0.50) | FAAHPDE10AHTR1AHCAR2 | |
| SCHEMBL27269314 | 0.80 | PDE10A (0.61) | FAAHPDE10APTK2MEN1KMT2A | |
| SCHEMBL7014186 | 0.80 | FAAH (0.42) | FAAHKCNH2 | |
| SCHEMBL1514937 | 0.78 | FAAH (0.44) | FAAHMEN1KMT2AKCNH2HCAR2 | |
| SCHEMBL5774709 | 0.76 | PTK2 (0.53) | FAAHHTR1APTK2DRD4NPC1 | |
| SCHEMBL3608360 | 0.75 | FAAH (1.00) | FAAH | |
| SCHEMBL5776029 | 0.74 | FAAH (0.46) | FAAHHTR1APTK2MEN1KMT2A | |
| SCHEMBL2927709 | 0.74 | MEN1 (0.73) | FAAHHTR1AMEN1KMT2AKCNH2 | |
| SCHEMBL5318658 | 0.73 | NPC1 (0.68) | MEN1KMT2AHCAR2NPC1RAB9A | |
| SCHEMBL5709396 | 0.72 | PDE10A (0.67) | PDE10AMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | claimed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | FAAH 2541/4885PDE10A 2419/4885HTR1A 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.